How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix

NEW YORK, NY / ACCESSWIRE / October 30, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked about situations on wall street today: Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Ekso Bionics Holdings, Inc. (OTC: EKSO) and Cellceutix Corp (OTC: CTIX).

Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full commentary is being made available to the public on a complimentary basis.

This release includes the following highlights:

ARNA from $1.21 on April 20, 2011 (+62% gain)

XOMA from $0.69 on August 24, 2015 (+87% increase)

EKSO from $0.75 on October 1, 2014 (+48.73% improvement)

CTIX from $0.10 on December 29, 2010 (now +1260.00% higher)

Did you want to hear about these companies before their big move? Trader's Choice studies patterns of success to discover the Trade of the Year, before the run.

============

Get 2015's TRADE of the YEAR

(You may have to copy and paste the link into your browser)

1 Year FREE Subscription Link: http://www.Traders-Choice.com/2015free

============

Highlights from today's analysis includes:

On Thursday, October 29, 2015, the U.S. markets finished weaker as NASDAQ ended at 5,074.27 down 0.42%, Dow Jones decreased 0.13% to finish the day at 17,755.80 and the S&P closed at 2,089.41 down 0.04%.

- On April 20, 2011, Arena Pharmaceuticals, Inc. was trading at USD 1.21, and has since experienced gains of 62%. Among multiple factors, the Company's persistent R&D efforts to bring innovative medicines targeting G protein-coupled receptors to patients have helped the stock to stay firm over the years. Shares of Arena Pharmaceuticals slipped by 10.91% to close Wednesday's session at USD 1.96. While oscillating between USD 1.90 and USD 2.18, the stock recorded a trading volume of 8.1 million shares, higher than its three months trading volume of 2.8 million. The recent stock gains can be attributed to Arena Pharmaceuticals prior day (October 27, 2015) announcement about its plans to improve efficiencies and reduce costs so as to focus on the advancement of its research and development priorities. As part of this initiative, the Company will reduce its US workforce by approximately 80 employees or 35%, which Arena estimates will reduce annualized cash expenditures for personnel by approximately USD 11.0 million. Further, the Company plans to implement additional cost control measures to further reduce its expenditures, including reductions at its Swiss manufacturing facility, Arena Pharmaceuticals GmbH.

- On August 24, 2015, XOMA Corporation was trading for USD 0.69 and has since increased 87%. The recent spike in the stock price can be attributed to development and commercialization agreement with Novartis for first-in-class anti-TGF-beta antibody program in immuno-oncology. On Wednesday, the stock of XOMA Corporation, ended 1.53% lower at USD 1.29. A total of 7.7 million shares exchanged hands, against its three months average volume of 5.5 million shares. During the session, shares fluctuated in the range of USD 1.22 and USD 1.38. Recently, on October 26, 2015, XOMA Corporation announced that it has initiated a Phase 2 proof-of-concept study to evaluate the safety and ability to prevent hypoglycemia (dangerously low blood sugar) of a single dose of XOMA 358 in patients with congenital hyperinsulinism (HI). The Company informed that XOMA 358 is a fully human allosteric monoclonal antibody that reduces insulin receptor activity. Paul Rubin, M.D., Senior Vice President, Research and Development, and Chief Medical Officer at XOMA, commented, "We are developing XOMA 358 as a first-in-class therapeutic for patients with this potentially fatal disease, and we are pleased to be conducting this study at a world-class medical center recognized for its leadership in treating HI patients."

- On October 1, 2014, Ekso Bionics Holdings, Inc., a robotic exoskeleton company, was trading for $0.75 and has since risen 48.73%. Shares of Ekso Bionics closed Wednesday's trading session at USD 1.12, reflecting a dip of 0.88% from the previous session. The company's shares oscillated in the range of USD 1.12 - USD 1.16 and recorded a trading volume of 0.259 million shares, relatively close to its 30 days average volume of 0.252 million shares. Most recently, (October 2, 2015) Ekso Bionics announced that it has been selected by Boston Dynamics, now part of Google, to continue developing technologies for Defense Advanced Research Projects Agency's (DARPA's) Warrior Web Task A project. This collaboration now brings the total amount of the grants awarded in the last twelve months to Ekso LabS(TM), the engineering services division of Ekso Bionics, to $4.5 million of non-dilutive funding. A day earlier (October 1, 2015) Ekso Bionics Holdings informed about the appointment of senior medical device executive Ruediger Hausherr for its Europe, Middle East, Africa (EMEA) markets. Mr. Hausherr has around 20 years experience and has brought novel new therapies to market in executive leadership positions in the Orthopedic field.

- On December 29, 2010, Cellceutix Corp was trading for $0.10 and has since increased 1260%. Shares of Cellceutix Corp ended 1.87% higher to close Wednesday's session at USD 1.36. While oscillating between USD 1.29 and USD 1.37 during the session, the stock recorded a trading volume of 0.24 million shares. Recently on October 13, 2015, the Company informed that it continues to progress towards starting a phase 3 study for Brilacidin intravenous (IV) in the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). In September, Cellceutix submitted its initial Pediatric Study Plan (PSP) to the Food and Drug Administration (FDA) for the use of Brilacidin IV in the treatment of ABSSSI in children. The submission of the PSP is the first of many requirements in expanding the use of Brilacidin to children. As part of its other phase 3 start-up activities, the Company received the Brilacidin active pharmaceutical (API) from its contracted manufacturer which is currently undergoing additional rigorous laboratory testing by Company's vendors. Cellceutix informed that the goal of phase 3 is to confirm the safety and efficacy of single-dose Brilacidin IV against a commonly used antibiotic in large groups of ABSSSI patients worldwide.

Why Trader's Choice?

"Give yourself an advantage in today's market."

"In order to become successful, you need to have information as it happens and understand how it plays out into future stock price. This is our expertise. We know what moves markets. We understand what makes a winner. We translate our extensive research and years of experience into easy-to-understand emails for our subscribers."

"Don't waste time trying to figure it out for yourself; tip the scales in your favor and add our experience to your team. Subscription to our complementary real-time newsletter is free for 1-year and instantly available at http://www.Traders-Choice.com/2015free."

About Trader's Choice:

Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press (at) traders-choice.com

SOURCE: Trader's Choice




Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.